nach oben

Erschienen in:

02.08.2017 | Original Article

Microablative fractional CO₂ laser for the genitourinary syndrome of menopause: power of 30 or 40 W?

verfasst von: Eleni Pitsouni, Themos Grigoriadis, Matthew Falagas, Angeliki Tsiveleka, Stefano Salvatore, Stavros Athanasiou

Erschienen in: Lasers in Medical Science | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

This retrospective case-control study aimed to compare 30 versus 40 W power of CO₂ laser for the therapy of genitourinary syndrome of menopause (GSM). Postmenopausal women with severe intensity of dyspareunia and dryness were eligible to be included in this study. Primary outcomes were dyspareunia and dryness. Secondary outcomes were itching/burning, dysuria, frequency and urgency, Female Sexual Function Index (FSFI), vaginal maturation value (VMV), and Vaginal Health Index Score (VHIS). One laser therapy was applied every month for 3 months. Outcomes were evaluated at baseline and 1 month following the 3rd therapy. Fifty (25 per group) women were included in this study. In the 30-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.0 ± 1.9, 5.9 ± 2.0, 16.6 ± 6.7, 29.9 ± 13.0, and 11.0 ± 2.9, respectively (within group comparisons all p < 0.001). In the 40-W group, mean improvement of dyspareunia, dryness, itching/burning, FSFI, VMV, and VHIS was 6.1 ± 1.7, 6.5 ± 2.0, 5.2 ± 2.5, 14.8 ± 7.1, 25.0 ± 13.4, and 10.5 ± 4.1, respectively (within-group comparisons, all p ≤ 0.001). Comparison between 30 and 40 W revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. CO₂ laser therapy may improve GSM symptoms and clinical signs. This improvement did not seem to associate to power of 30 or 40 W.

Portman DJ, Gass MLS, on behalf of the Vulvovaginal Atrophy Terminology Consensus Conference Panel (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause 21:1063–1068CrossRefPubMed

Ward K, Deneris A (2016) Genitourinary syndrome of menopause: a new name for an old condition. Nurse Pract 41:28–33CrossRefPubMed

Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, Rees M (2015) Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 82:308–313CrossRefPubMed

Stefano S, Stavros A, Massimo C (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27:504–508PubMed

Hutchinson-Colas J, Segal S (2015) Genitourinary syndrome of menopause and the use of laser therapy. Maturitas 82:342–345CrossRefPubMed

http://www.monalisatouch.com/wp-content/uploads/2016/12/Smartxide2-V2LR-Brochure-ING-Rev-12.2.pdf. Accessed at 05/05/2017

Salvatore S, Leone Roberti Maggiore U, Origoni M, Parma M, Quaranta L, Sileo F, Cola A, Baini I, Ferrero S, Candiani M, Zerbinati N (2014) Microablative fractional CO₂ laser improves dyspareunia related to vulvovaginal atrophy: a pilot study. J Endom Pelv Pain Disord 6:150–156

Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, Marotta F, Calligro A (2015) Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 22:845–849

Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U (2014) A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 17:363–369CrossRefPubMed

10.

Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zebinati N, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U (2015) Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy. Climacteric 18:219–225CrossRefPubMed

11.

Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, Saitta S, Calagna G (2015) Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 80:296–301CrossRefPubMed

12.

Pieralli A, Fallani MG, Becorpi A, Bianchi C, Corioni S, Longinotti M, Tredici Z, Guaschino S (2016) Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 294:841–846CrossRefPubMed

13.

Perino A, Cucinella G, Gugliotta G, Saitta S, Politi S, Adie B, Marci R, Calagna G (2016) Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Med Pharmacol Sci 20:841–846

14.

Sokol ER, Karram MM (2016) An assessment of the safety and efficacy of fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 23:1102–1107CrossRefPubMed

15.

Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, Grigoriadis T (2016) The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric 19:512–518CrossRefPubMed

16.

Pitsouni E, Grigoriadis T, Tsiveleka A, Zacharakis D, Salvatore S, Athanasiou S (2016) Microablative fractional CO2 laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas 94:131–136CrossRefPubMed

17.

Murina F, Karram M, Salvatore S, Felice R (2016) Fractional CO2 laser treatment of the vestibule for patients with vestibulodynia and genitourinary syndrome of menopause: a pilot study. J Sex Med 13:1915–1917CrossRefPubMed

18.

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R Jr (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26:191–208CrossRefPubMed

19.

Wiegel M, Meston C, Rose R (2005) The female sexual function index (FSFI): cross validation and development of clinical cutoff scores. J Sex Marital Ther 31:1–20CrossRefPubMed

20.

Athanasiou S, Grigoriadis T, Kyriakidou N, Giannoulis G, Antsaklis A (2012) The validation of international consultation on incontinence questionnaires in the Greek language. Neurourol Urodyn 31:1141–1144CrossRefPubMed

21.

Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL (2004) The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a National Community Survey. Value Health 7:455–463CrossRefPubMed

22.

Lukacz ES, Whitcomb EL, Lawrence JM, Nager CW, Luber KM (2009) Urinary frequency in community-dwelling women: what is normal? Am J Obstet Gynecol 200:552.e1–552.e7CrossRef

23.

Weber MA, Limpens J, Roovers JPWR (2015) Assessment of vaginal atrophy: a review. Int Urogynecol J 26:15–28CrossRefPubMed

24.

Salvatore S, Leone Roberti Maggiore U, Athanasiou S, Origoni M, Candiani M, Calligaro A, Zerbinati N (2015) Histological study on the effects of microablative fractional CO₂ laser on atrophic vaginal tissue: an ex vivo study. Menopause 22:845–849CrossRefPubMed

25.

Campolmi P, Bonan P, Cannarozzo G, Bassi A, Bruscino N, Arunachalam M, Troiano M, Lotti T, Moretti S (2012) Highlights of thirty-year experience of CO₂ laser use at the Florence (Italy) department of dermatology. ScientifWorldJournal 2012:546528

26.

Nappi RE, Placios S, Panay N, Particco M, Krychman ML (2016) Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 19:188–197CrossRefPubMed

27.

Nappi RE, Kingsberg S, Maamari R, Simon J (2013) The CLOSER (clarifying vaginal atrophy’s impact on sex and relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 10:2232–2241CrossRefPubMed

28.

Nappi RE, Kokot-Kierepa M (2012) Vaginal health insights, views and attitudes (VIVA)—results from an international survey. Climacteric 1:36–44CrossRef

29.

Palma F, Volpe A, Villa P, Cagnacci A, as the writing group of the AGATA study (2016) Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 83:40–44CrossRefPubMed

30.

Ettinger B, Hait H, Reape KZ, Shu H (2008) Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 15:885–889CrossRefPubMed

31.

Santoro N, Komi J (2009) Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 6:2133–2142CrossRefPubMed

32.

Kingsberg SA, Wysocki S, Magnus L, Krychman ML (2013) Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med 10:1790–1799CrossRefPubMed

33.

Ballagh SA (2005) Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 23:126–140CrossRefPubMed

34.

Chollet JA (2011) Efficacy and safety of ultra-low-dose Vagifem (10mcg). Patient Prefer Adherence 5:571–574CrossRefPubMedPubMedCentral

35.

Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M (2003) Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 82:187–197CrossRefPubMed

36.

Lose G, Englev E (2000) Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 107:1029–1034CrossRefPubMed

37.

Weber MA, Lim V, Oryszczyn J, Te West N, Souget J, Jefery S, Roovers JP, Moore KH (2017) The effect of vaginal oestriol cream on subjective and objective symptoms of stress urinary incontinence and vaginal atrophy: an international multi-centre pilot study. Gynecol Obstet Investig 82:15–21CrossRef

38.

Murina F, Graziottin A, Felice R, Di Francesco S (2016) Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? Eur J Obstet Gynecol Rerod Biol 207:121–124CrossRef

39.

Hosseinzadeh P, Ghahiri A, Daneshmand F, Ghasemi M (2015) A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran 2010-2012. J Res Med Sci 20:1160–1165CrossRefPubMedPubMedCentral

Titel: Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?
verfasst von: Eleni Pitsouni
Themos Grigoriadis
Matthew Falagas
Angeliki Tsiveleka
Stefano Salvatore
Stavros Athanasiou
Publikationsdatum: 02.08.2017
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 8/2017
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-017-2293-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Human adipose-derived stem cell spheroid treated with photobiomodulation irradiation accelerates tissue regeneration in mouse model of skin flap ischemia

Effect of photobiomodulation therapy on reducing the chemo-induced oral mucositis severity and on salivary levels of CXCL8/interleukin 8, nitrite, and myeloperoxidase in patients undergoing hematopoietic stem cell transplantation: a randomized clinical trial

Effect of a photosensitization reaction performed during the first 3 min after exposure of rat myocardial cells to talaporfin sodium in vitro

Efficacy of fractional lasers in treating alopecia: a literature review

Photobiomodulation therapy action in wound repair skin induced in aged rats old: time course of biomarkers inflammatory and repair

Enhancing hair growth in male androgenetic alopecia by a combination of fractional CO2 laser therapy and hair growth factors